<DOC>
	<DOCNO>NCT02123953</DOCNO>
	<brief_summary>The purpose study evaluate safety pharmacokinetics TAK-438 follow multiple oral dos healthy adult Japanese male participant</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics TAK-438 Healthy Male Participants</brief_title>
	<detailed_description>The drug test study call TAK-438 . TAK-438 test assess side effect TAK-438 move throughout body multiple dos administer . This study look lab result side effect people take TAK-438 . The study consist 5 step cover dose range TAK-438 10 , 15 , 20 , 30 40 mg daily 7 day . The study population step include 12 participant . Within step , 9 participant randomize TAK-438 3 participant randomize placebo . A total 60 participant enrol . The dose group study take place sequential order . Therefore , TAK-438 15 mg group start TAK-439 10 mg group complete , etc . All participant dose group ask take study drug morning , fast least 10 hour , day throughout study . This single-centre trial conduct Japan . The overall time participate study 43 day . Participants make 3 visit clinic , include one 11-day period confinement clinic , final visit 7 day last dose study drug follow-up assessment .</detailed_description>
	<criteria>1 . Healthy adult Japanese male volunteer . 2 . Is 2045 year old inclusive , time give consent . 3 . Is capable understand comply protocol requirement . 4 . Signs write , informed consent form prior initiation study procedure . 5 . Weighs least 50 kg body mass index ( BMI ) 18.5 25.0 kg/m^2 inclusive screening . 6 . Tests negative hepatitis B surface antigen ( HBs ) , hepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antigenantibody syphilis serum reaction test . 7 . The participant investigator subinvestigator confirm eligible participate study base result screen test , physical examination , physical finding , vital sign , electrocardiogram ( ECG ) , clinical laboratory test etc . 3 day dose start dose Day 1 study drug . 1 . Has undergone upper gastrointestinal resectioning vagetomy . 2 . Is judged hypoacidity anacidity . 3 . Presently history acidrelated disease ( e.g. , erosive esophagitis , duodenal ulcer , gastric ulcer , nonerosive esophagitis , Barrett 's esophagitis ZollingerEllison syndrome ) . 4 . Received H. pylori eradication treatment within 6 month prior start treatment study drug . 5 . Presently history hepatic disorder , renal disorder , cardiovascular system disease , blood disease , endocrine disease , metabolic disease , lung disease , gastrointestinal disease , nervous system disease , urological disease , immunological disease mental illness make eligible participate study . 6 . Presently history hypersensitivity allergy towards drug food . 7 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 5 year prior start treatment study drug . 8 . Participant difficult collect blood peripheral vein . 9 . Has donate 200 mL whole blood within 4 week ( 28 day ) 400 mL whole blood within 12 week ( 84 day ) prior start treatment study drug . 10 . Has donate total volume 800 mL whole blood within 52 week ( 364 day ) prior start treatment study drug . 11 . Has give plasma component plaque component within 2 week ( 14 day ) prior start treatment study drug . 12 . Has use prescription drug ( include overthe counter drug ) within 4 week ( 28 day ) prior start treatment study drug . 13 . Has use vitamin , Chinese herbal remedy , supplement ( include St John 's Wort , ginseng , kava kava , ginkgo biloba , melatonin ) within 4 week ( 28 day ) prior start treatment study drug . 14 . Has ingest food beverage contain grapefruit ( juice pulp ) , caffeine , alcohol within 72 hour prior start treatment study drug . 15 . Administered another study drug within 16 week ( 112 day ) prior start treatment study drug . 16 . Administered TAK438 past . 17 . Is consider investigator subinvestigator , reason , unsuitable candidate participating study</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>